Woodcock awarded grant to study markers of immunotherapy response in lung cancer

July 23, 2019

The Lung Cancer Initiative of North Carolina has awarded $25,000 to Mark Woodcock, MD, to support a research effort to identify characteristics of lung cancer patients who will respond to treatments that unlock the immune system against cancer. Woodcock, a fellow in the UNC School of Medicine Division of Hematology/Oncology, was awarded a 2019-20 Lung … Continued

By forming clots in tumors, immune cells aid lung cancer’s spread

May 24, 2018

Researchers led by UNC Lineberger’s Chad Pecot, MD, report in the journal Nature Communications that for a particular subset of lung cancer tumors, there is a high prevalence of immune cells called inflammatory monocytes. These cells, which normally help to build clotting scaffolds to promote wound healing, also make it possible for tumor cells to migrate and spread to other parts of the body.

Pecot awarded $400,000 Free to Breathe grant

January 31, 2017

Funding will support research to evaluate whether targeting inflammatory monocytes through the use of CCR2 inhibitors will blunt or prevent metastasis in squamous cell lung cancer.

UNC pulmonology fellow wins grant for lung cancer research

July 7, 2015

Adam Belanger, MD, a second-year pulmonology fellow in pulmonary diseases and critical care medicine at the UNC School of Medicine, was one of four North Carolina researchers to win a research grant from the Lung Cancer Initiative of North Carolina’s Research Fellows Program.

Bobby Kadis: Living life to the fullest

May 15, 2015

These days Bobby Kadis is living life to the fullest. After being diagnosed with Stage 4 lung cancer, he enrolled in a UNC Lineberger clinical trial using a combination of targeted drug therapies. Now the avid potter, mountain climber and yoga enthusiast celebrates being cancer-free.

Bobby Kadis

May 13, 2015

These days Bobby Kadis is living life to the fullest. After being diagnosed with Stage 4 lung cancer, he enrolled in a UNC Lineberger clinical trial using a combination of targeted drug therapies. Now the avid potter, mountain climber and yoga enthusiast celebrates life to its fullest.